Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, raised $19 million by offering 4.8 million shares at $4, below the last close of its shares on the OTCQB (PCSA). The company most recently filed to offer 3.9 million...read more
Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, lowered the proposed deal size for its upcoming IPO on Wednesday. The Hanover, MD-based company now plans to raise $16 million by offering 3.2 million shares at a...read more
Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, lowered the proposed deal size for its upcoming IPO on Thursday. In its latest filing
The Hanover, MD-based company now plans to raise $18 million by offering 2...read more
Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, announced terms for its IPO on Friday. The Hanover, MD-based company plans to raise $20 million by offering 2.5 million shares at a price range of $7 to $9. At the...read more
Nano-cap skin disease biotech Processa Pharmaceuticals prices Nasdaq uplisting at $4
Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, raised $19 million by offering 4.8 million shares at $4, below the last close of its shares on the OTCQB (PCSA). The company most recently filed to offer 3.9 million...read more
Nano-cap skin disease biotech Processa Pharmaceuticals slashes valuation by 35% ahead of $16 million Nasdaq uplisting
Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, lowered the proposed deal size for its upcoming IPO on Wednesday. The Hanover, MD-based company now plans to raise $16 million by offering 3.2 million shares at a...read more
Skin disease biotech Processa Pharmaceuticals lowers deal size ahead of $18 million Nasdaq uplisting
Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, lowered the proposed deal size for its upcoming IPO on Thursday. In its latest filing The Hanover, MD-based company now plans to raise $18 million by offering 2...read more
Skin disease biotech Processa Pharmaceuticals sets terms for $20 million IPO
Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, announced terms for its IPO on Friday. The Hanover, MD-based company plans to raise $20 million by offering 2.5 million shares at a price range of $7 to $9. At the...read more